Stocks to Watch: Nvidia Partners with SK Hynix, Marvell and Flex Join S&P 500
Several companies are experiencing notable stock movements due to partnerships and index changes, which could influence investor sentiment and market dynamics.
Roche
Price: 50.42Company and Business Model
Roche is a global healthcare company specializing in pharmaceuticals and diagnostics. Its core products include prescription medications, particularly in oncology, immunology, and neuroscience, as well as diagnostic tools for various diseases. Major business segments are Pharmaceuticals and Diagnostics, with primary revenue sources stemming from drug sales and diagnostic testing services. The company is known for its strong research and development capabilities, contributing to its innovative product pipeline.
Investment Profile
Roche's investment profile is characterized by a balanced approach, appealing to investors seeking both growth and dividends. The company offers a stable dividend yield, making it attractive for income-focused investors, while its strong revenue growth indicates potential for capital appreciation. This combination positions Roche as suitable for those looking for a reliable investment with moderate risk.
Fundamental metrics (experimental)
- EPS (TTM) — earnings per share for the last 12 months, $
- 2.73 OK
- Revenue QoQ — quarter-over-quarter revenue growth
- 90.4% ↑
- 20d volatility
- 1.8% stable
- Dividend yield
- 3.1% moderate last ex-date: 2026-03-13
FMP / FinFeed data updated:
2026-06-11
Reco: Buy
Potential: 63
Risk: 40
Updated: 2026-06-11 05:39
How recommendation works
Why AI thinks so:
Stable dividend, moderate growth, uncertain market conditions.
Track in portfolio
Price chart
AI recommendation
Analyst forecast
Calendar event
Positive signal
Negative signal
Neutral / update
Hold / informational
B My buy
S My sell
AI recommendation changes
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-06-05 02:47 | Sell | Buy | Strong revenue growth, but mixed momentum signals. |
| 2026-06-03 02:51 | Hold | Sell | Weak momentum and high risk limit upside potential. |
| 2026-06-01 02:49 | Buy | Hold | Solid fundamentals, but mixed momentum signals present uncertainty. |
Analyst forecasts
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2025-12-10 11:17 | HSBC | Target Raised | 50 → 57 | 48.66 |
| 2025-10-02 09:07 | HSBC | Rating Upgraded | — → 50 | 44.83 |
Генеральный директор Roche Томас Шинеккер выражает обеспокоенность по поводу укрепления швейцарского франка на фоне падения продаж
Компания Roche сообщила о снижении продаж в первом квартале, что связано с укреплением швейцарского франка и конкуренцией со стороны дженериков для некоторых старых препаратов.